Best Telehealth Clinics in Illinois (2026)

Illinois telehealth is governed by 225 ILCS 150, the Illinois Telehealth Act. The state requires an in-person evaluation before prescribing Schedule II through V controlled substances via telehealth under state law. The federal DEA extension through December 31, 2026 overrides this requirement, allowing telehealth prescribing of testosterone (Schedule III) and other controlled substances without a prior in-person visit while the waiver is active.

HB 3308 (Public Act 102-0104), signed by Governor Pritzker on July 22, 2021, permanently codified payment parity for mental health and substance use disorder telehealth services. Broader telehealth parity was extended through 2027 under the same legislation but was not made fully permanent. This means private insurers must reimburse telehealth at the same rate as in-person care for most services through at least 2027.

Illinois is an active member of the Interstate Medical Licensure Compact, which gives the state access to a large pool of out-of-state physicians through the expedited licensing pathway. This contributes to strong provider availability.

Prescribers must participate in the Illinois Prescription Monitoring Program (PMP) before prescribing controlled substances. The standard of care applies equally to telehealth and in-person encounters. Illinois does not have a separate state-level restriction on compounded medications beyond the federal FDA framework for 503A and 503B pharmacies.

One thing worth watching: when the DEA extension expires, Illinois patients starting TRT or other controlled substance programs via telehealth may need an in-person evaluation to continue. Providers with physical clinic networks or lab partnerships will have an advantage at that point.

Illinois has 12.8 million residents and is the sixth-largest state. Provider coverage is strong thanks to IMLC membership and a large urban market centered on Chicago. Of the 64 providers tracked on ClinicLayer, roughly 56 serve Illinois.

All major TRT providers are available. Maximus ($100/mo with labs, all 50 states), Hone Health ($25/mo entry, all 50 states), TRT Nation ($99/mo, serves 45 states including IL), BraverX ($129/mo with labs), PeterMD ($99/mo annual with labs), DudeMeds ($77/mo), and Titan Medical ($99/mo) all serve the state. Defy Medical ($200/mo) and Marek Health ($166/mo) are also available for premium TRT.

GLP-1 availability is unrestricted. No semaglutide or tirzepatide limitations apply in Illinois. Embody ($99/mo), SkinnyRx ($99/mo), DirectMeds ($199/mo), Zealthy ($99/mo), Remedy Meds ($179/mo), GobyMeds ($119/mo), Sesame Care, MEDVi ($179/mo first month), Shed ($199/mo), Sunlight ($179/mo), and Mochi Health ($99/mo membership) all serve the state.

All HRT providers serve Illinois. Midi Health accepts insurance. PlushCare ($20/mo membership) accepts major insurers. All hair loss and ED providers are available. Enhance MD excludes 11 states but does not appear to exclude Illinois. Peptide providers like Maximus and Defy Medical serve the state.

Feel30 lists "Most US states" and excludes 16 states for TRT. Illinois is not clearly excluded but patients should verify directly. Feel30's enclomiphene service covers all 50 states.

TRT pricing in Illinois matches national rates. DudeMeds at $77/mo (labs $200 extra, true annual $1,124) is the cheapest monthly option. PeterMD at $99/mo annual ($1,188/year with labs included, requires upfront payment) is the cheapest all-in option. Maximus is $100/mo with labs on the annual plan ($1,300/year). TRT Nation is $99/mo with labs at $258 extra ($1,446/year). BraverX is $129/mo with labs ($1,548/year). The premium end reaches $2,800/year with Defy Medical.

GLP-1 starts at $99/mo (Embody, SkinnyRx, Zealthy) and goes up to $399/mo (TrimRx). GobyMeds at $119/mo and Fridays at $117/mo are budget-friendly compounded semaglutide options. The median price across providers is roughly $179/mo.

Illinois Medicaid does not cover GLP-1 medications for weight loss. Coverage is limited to type 2 diabetes indications (Ozempic, Mounjaro). Illinois state employee health plans were required to cover weight-loss injectables effective July 1, 2024 under separate legislation, but this is distinct from Medicaid.

Illinois does not tax prescription medications. Telehealth consultations are not subject to state sales tax on services. The state has a flat income tax rate of 4.95%.

HRT ranges from $0 (Midi Health with insurance) to $149/mo (Hone Premium). ED starts at $17/mo (Hims) and goes up to $119/mo (MEDVi quad formula). Hair loss starts at $20/mo (Hims) and tops out at $88/mo (Nutrafol).

TRT (testosterone replacement therapy)

Illinois state law requires an in-person evaluation before telehealth prescribing of controlled substances. The federal DEA waiver through December 2026 overrides this. Testosterone (Schedule III) can currently be prescribed via telehealth without an in-person visit. Both compounded and FDA-approved testosterone are available. Illinois PMP must be checked before prescribing. Delivery methods include injection, cream, oral, and enclomiphene.

GLP-1 weight loss

No state-specific restrictions on semaglutide or tirzepatide in Illinois. Federal FDA compounding rules apply. Compounded semaglutide availability tightened after the FDA shortage resolution in February 2025. Illinois has no additional state-level compounding restrictions. Illinois Medicaid does not cover weight-loss GLP-1s.

HRT (hormone replacement therapy)

HRT follows standard federal prescribing rules in Illinois. No additional state restrictions apply. All HRT providers serve the state. Midi Health accepts insurance in Illinois.

Hair loss

Hair loss treatment follows standard federal prescribing rules in Illinois. No additional state restrictions apply.

ED (erectile dysfunction)

ED treatment follows standard federal prescribing rules in Illinois. No additional state restrictions apply.

Peptides

Peptide therapy follows standard federal rules in Illinois. Sermorelin, BPC-157, and NAD+ are available from providers like Maximus (all 50 states), Defy Medical, and Marek Health. No state-specific peptide restrictions were identified.